                         SEQUENCE LISTING

<110>  Novo Nordisk A/S
 
<120>  SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST, AN SGLT2 INHIBITOR AND A SALT OF 
       N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID

<130>  190068WO01

<160>  6     

<170>  PatentIn version 3.5

<210>  1
<211>  31
<212>  PRT
<213>  Homo sapiens

<400>  1

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly 
            20                  25                  30      


<210>  2
<211>  40
<212>  PRT
<213>  Heloderma suspectum

<400>  2

His Gly Glu Gly Thr Phe Ile Thr Ser Asp Leu Ser Lys Gln Met Glu 
1               5                   10                  15      


Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro 
            20                  25                  30          


Ser Ser Gly Ala Pro Pro Pro Ser 
        35                  40  


<210>  3
<211>  29
<212>  PRT
<213>  Homo sapiens

<400>  3

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  4
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MOD_RES
<222>  (20)..(20)
<223>  The amino acid residue is modified with a substituent.

<400>  4

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly 
            20                  25                  30      


<210>  5
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MOD_RES
<222>  (20)..(20)
<223>  The amino acid residue is modified with a substituent.

<220>
<221>  MOD_RES
<222>  (31)..(31)
<223>  The amino acid residue is modified with a substituent.

<400>  5

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Lys 
            20                  25                  30      


<210>  6
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MOD_RES
<222>  (21)..(21)
<223>  The amino acid residue is modified with a substituent

<220>
<221>  MOD_RES
<222>  (30)..(30)
<223>  The amino acid residue is modified with a substituent

<400>  6

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu 
1               5                   10                  15      


Gln Ala Ala Arg Lys Phe Ile Gly Trp Leu Val Arg Gly Lys Gly Glu 
            20                  25                  30          


Gly 
    


